CorMedix Net Worth
CorMedix Net Worth Breakdown | CRMD |
CorMedix Net Worth Analysis
CorMedix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CorMedix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CorMedix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CorMedix's net worth analysis. One common approach is to calculate CorMedix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CorMedix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CorMedix's net worth. This approach calculates the present value of CorMedix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CorMedix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CorMedix's net worth. This involves comparing CorMedix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CorMedix's net worth relative to its peers.
Enterprise Value |
|
To determine if CorMedix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CorMedix's net worth research are outlined below:
| CorMedix appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (46.34 M) with profit before overhead, payroll, taxes, and interest of 61.67 K. | |
| CorMedix currently holds about 64.62 M in cash with (38.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. | |
| CorMedix has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Cormedix EVP Elizabeth Hurlburt sells 1.57m in stock |
CorMedix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CorMedix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CorMedix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know CorMedix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CorMedix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CorMedix backward and forwards among themselves. CorMedix's institutional investor refers to the entity that pools money to purchase CorMedix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 367.6 K | D. E. Shaw & Co Lp | 2024-09-30 | 321 K | Spinnaker Capital Llc | 2024-06-30 | 175.4 K | Nuveen Asset Management, Llc | 2024-06-30 | 170.3 K | Barclays Plc | 2024-06-30 | 162 K | Bank Of New York Mellon Corp | 2024-06-30 | 158.9 K | Charles Schwab Investment Management Inc | 2024-09-30 | 156.5 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 152.3 K | Steward Partners Investment Advisory, Llc | 2024-06-30 | 142.7 K | Blackrock Inc | 2024-06-30 | 3.6 M | Vanguard Group Inc | 2024-09-30 | 3.1 M |
Follow CorMedix's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 604.34 M.Market Cap |
|
Project CorMedix's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.56) | (0.59) | |
| Return On Capital Employed | (0.69) | (0.73) | |
| Return On Assets | (0.56) | (0.59) | |
| Return On Equity | (0.66) | (0.63) |
When accessing CorMedix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CorMedix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CorMedix's profitability and make more informed investment decisions.
Please note, the presentation of CorMedix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CorMedix's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CorMedix's management manipulating its earnings.
Evaluate CorMedix's management efficiency
CorMedix has return on total asset (ROA) of (0.3769) % which means that it has lost $0.3769 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. CorMedix's management efficiency ratios could be used to measure how well CorMedix manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.59. In addition to that, Return On Capital Employed is expected to decline to -0.73. At present, CorMedix's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 108.2 K, whereas Other Current Assets are forecasted to decline to about 725 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.38 | 1.45 | |
| Tangible Book Value Per Share | 1.38 | 1.45 | |
| Enterprise Value Over EBITDA | (3.04) | (3.19) | |
| Price Book Value Ratio | 2.73 | 2.87 | |
| Enterprise Value Multiple | (3.04) | (3.19) | |
| Price Fair Value | 2.73 | 2.87 | |
| Enterprise Value | 148.4 M | 155.8 M |
CorMedix has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 45.5767 | Revenue 12.3 M | Quarterly Revenue Growth (0.47) | Revenue Per Share 0.212 | Return On Equity (0.65) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CorMedix insiders, such as employees or executives, is commonly permitted as long as it does not rely on CorMedix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CorMedix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CorMedix Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 8th of October 2024 Other Reports | ViewVerify |
CorMedix Earnings per Share Projection vs Actual
CorMedix Corporate Management
| Kaufman Esq | Chief VP | Profile | |
| Joseph MBA | CEO Director | Profile | |
| Donna Ucci | Senior Quality | Profile | |
| Tushar Mukherjee | Senior Operations | Profile | |
| Phoebe Esq | Gen EVP | Profile | |
| Elizabeth BA | Executive Affairs | Profile | |
| Erin Mistry | Executive Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.